Abbott Labs (ABT) TMVR Gets CMS Reimbursement Review; Goldman Positive
Tweet Send to a Friend
Goldman Sachs on Tuesday maintained a Buy rating on Abbott Labs (NYSE: ABT) with a price target of $42.00. Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
